These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 20304468)

  • 1. Serum tetranectin as a preoperative indicator for postoperative complications in Danish ovarian cancer patients.
    Begum FD; Høgdall E; Christensen IJ; Christensen L; Kjaer SK; Blaakaer J; Petri AL; Høgdall C
    Gynecol Oncol; 2010 Jun; 117(3):446-50. PubMed ID: 20304468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum tetranectin is a significant prognostic marker in ovarian cancer patients.
    Begum FD; Høgdall E; Christensen IJ; Kjaer SK; Blaakaer J; Christensen L; Høgdall C
    Acta Obstet Gynecol Scand; 2010; 89(2):190-8. PubMed ID: 20121334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer.
    Høgdall CK; Nørgaard-Pedersen B; Mogensen O
    Anticancer Res; 2002; 22(3):1765-8. PubMed ID: 12168866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
    Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
    Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of pretherapeutic tetranectin and CA-125 in patients with relapse of ovarian cancer.
    Deng X; Høgdall EV; Høgdall CK; Nørgaard-Pedersen B; Jørgensen M; Nielsen H; Engelholm SA
    Gynecol Oncol; 2000 Dec; 79(3):416-9. PubMed ID: 11104612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
    Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
    Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study.
    Høgdall EV; Ryan A; Kjaer SK; Blaakaer J; Christensen L; Bock JE; Glud E; Jacobs IJ; Høgdall CK
    Cancer; 2004 Jun; 100(11):2387-95. PubMed ID: 15160342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P53 mutations in tissue from Danish ovarian cancer patients: from the Danish "MALOVA" ovarian cancer study.
    Høgdall EV; Kjaer SK; Blaakaer J; Christensen L; Glud E; Vuust J; Høgdall CK
    Gynecol Oncol; 2006 Jan; 100(1):76-82. PubMed ID: 16183105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human tetranectin: methodological and clinical studies.
    Høgdall CK
    APMIS Suppl; 1998; 86():1-31. PubMed ID: 9868384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correlation of preoperative serum vascular endothelial growth factor level with CA125 level in patients with epithelial ovarian cancer and its prognostic value].
    Tan XJ; Lang JH; Shen K; Wang L; Wu M; Xu XY
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):9-12. PubMed ID: 18366924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective study of preoperative CA 125 levels in 82 patients with ovarian cancer.
    Rossi AC; Di Vagno G; Cormio G; Cazzolla A; Stefanelli S; D'Elia E; Selvaggi L
    Arch Gynecol Obstet; 2004 May; 269(4):263-5. PubMed ID: 14745561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish "Malova" Ovarian Cancer Study.
    Høgdall EV; Kjaer SK; Glud E; Christensen L; Blaakaer J; Vuust J; Bock JE; Norgaard-Pedersen B; Hogdall CK
    Anticancer Res; 2003; 23(4):3397-404. PubMed ID: 12926080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type I and III collagen metabolites as predictors of clinical outcome in epithelial ovarian cancer.
    Santala M; Simojoki M; Risteli J; Risteli L; Kauppila A
    Clin Cancer Res; 1999 Dec; 5(12):4091-6. PubMed ID: 10632345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.
    Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Bock JE; Glud E; Nørgaard-Pedersen B; Høgdall CK
    Cancer; 2003 Jul; 98(1):66-73. PubMed ID: 12833457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative predictors for residual tumor after surgery in patients with ovarian carcinoma.
    de Jong D; Eijkemans MJ; Lie Fong S; Gerestein CG; Kooi GS; Baalbergen A; van der Burg ME; Burger CW; Ansink AC
    Oncology; 2007; 72(5-6):293-301. PubMed ID: 18198490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis.
    Makar AP; Kristensen GB; Kaern J; Børmer OP; Abeler VM; Tropé CG
    Obstet Gynecol; 1992 Jun; 79(6):1002-10. PubMed ID: 1579296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum tetranectin and CA125 in endometrial adenocarcinoma.
    Lundstrøm MS; Høgdall CK; Nielsen AL; Nyholm HC
    Anticancer Res; 2000; 20(5C):3903-6. PubMed ID: 11268474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative serum fibrinogen level predicts postoperative pulmonary complications after lung cancer resection.
    Song SW; Lee HS; Kim MS; Lee JM; Kim JH; Nam BH; Zo JI
    Ann Thorac Surg; 2006 Jun; 81(6):1974-81. PubMed ID: 16731116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
    Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
    Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.